By day 21 post-tumor implant, CD8+ T cells expressed significantly less PD-1 after N-803 + αPD-L1 than PBS treatment (Additional file 1: Figure S9), suggesting they may be less exhausted. The gene discussed is CD8A; the disease is neoplasm.